Patents by Inventor William W. Cruikshank
William W. Cruikshank has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8398973Abstract: This invention provides methods and compositions for preventing post-surgical adhesion formation based on use of an interleukin-16 (IL-16) antagonist, including an IL-16 antagonist peptide and/or an IL-16 antagonist antibody.Type: GrantFiled: April 16, 2009Date of Patent: March 19, 2013Assignee: Trustees of Boston UniversityInventors: William W. Cruikshank, David M. Center
-
Publication number: 20120213790Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: March 20, 2012Publication date: August 23, 2012Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 8153121Abstract: The invention provides a method of reducing the severity of an autoimmune condition associated with T-lymphocyte infiltration. The invention also provides a method of diagnosing or predicting the susceptibility to an autoimmune disease associated with fibroblast mediated T-lymphocyte infiltration. Methods of identifying a substance capable of modulating T-lymphocyte recruitment associated with an autoimmune condition also are provided.Type: GrantFiled: May 6, 2002Date of Patent: April 10, 2012Assignee: Los Angeles Biomedical Research Institute at Harbor—UCLA Medical CenterInventors: Terry J. Smith, William W. Cruikshank
-
Publication number: 20110207679Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: February 18, 2011Publication date: August 25, 2011Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7998681Abstract: The present invention describes diagnosis and treatment of antibody-mediated inflammatory auto-immune diseases. The biochemical mechanisms underlying such disorders are described as characteristic molecular markers and antibody-mediated ligand-receptor interactions. Specifically, the activation of T-cells by disease specific IgG binding to the IGF-1 receptor is shown to underlie thyroid associated ophthalmopathy associated with Graves' disease and rheumatoid arthritis. Diagnostics for detection of disease are provided, as are therapeutics based on the determination of the mechanisms underlying a particular pathology.Type: GrantFiled: January 3, 2002Date of Patent: August 16, 2011Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Terry J. Smith, William W. Cruikshank
-
Publication number: 20110123526Abstract: This invention provides methods and compositions for preventing post-surgical adhesion formation based on use of an interleukin-16 (IL-16) antagonist, including an IL-16 antagonist peptide and/or an IL-16 antagonist antibody.Type: ApplicationFiled: April 16, 2009Publication date: May 26, 2011Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: William W. Cruikshank, David M. Center
-
Patent number: 7914778Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: GrantFiled: March 16, 2007Date of Patent: March 29, 2011Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20100008936Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: March 16, 2007Publication date: January 14, 2010Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7608691Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: GrantFiled: October 6, 2006Date of Patent: October 27, 2009Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7232801Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.Type: GrantFiled: June 27, 2005Date of Patent: June 19, 2007Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7208149Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: GrantFiled: February 5, 2003Date of Patent: April 24, 2007Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7019118Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.Type: GrantFiled: August 15, 2001Date of Patent: March 28, 2006Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 6936426Abstract: The present invention describes a method to detect connective tissue pathologies associated with Graves' disease ophthalmopathy and other antibody mediated inflammatory autoimmune diseases. The detection method comprises obtaining a sample from a patient suffering from an antibody-mediated inflammatory autoimmune disorder and measuring Interleukin 16 (IL-16) or RANTES produced by thyroid associated ophthalmopathy fibroblasts to indicate the presence or severity.Type: GrantFiled: October 19, 2001Date of Patent: August 30, 2005Assignee: Harbor-UCLA Research and Education InstituteInventors: Terry J. Smith, William W. Cruikshank
-
Patent number: 6723697Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.Type: GrantFiled: August 15, 2001Date of Patent: April 20, 2004Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 6699466Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16-mediated disorders such as certain inflammatory diseases.Type: GrantFiled: August 5, 1999Date of Patent: March 2, 2004Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20030153504Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: February 5, 2003Publication date: August 14, 2003Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20030096317Abstract: The present invention describes diagnosis and treatment of antibody-mediated inflammatory auto-immune diseases. The biochemical mechanisms underlying such disorders are described as characteristic molecular markers and antibody-mediated ligand-receptor interactions. Specifically, the activation of T-cells by disease specific IgG binding to the IGF-1 receptor is shown to underlie thyroid associated ophthalmopathy associated with Graves' disease and rheumatoid arthritis. Diagnostics for detection of disease are provided, as are therapeutics based on the determination of the mechanisms underlying a particular pathology.Type: ApplicationFiled: January 3, 2002Publication date: May 22, 2003Inventors: Terry J. Smith, William W. Cruikshank
-
Publication number: 20030022911Abstract: The present invention describes a novel therapy to modulate the connective tissue pathologies associated with Graves' disease ophthalmopathy and other antibody-mediated inflammatory auto-immune diseases. The therapy comprises administering to a patient suffering from an antibody-mediated inflammatory auto-immune disorder an Interleukin 16 (IL-16) activity inhibitor and/or a RANTES activity inhibitor in order to decrease the proliferation of CD4-bearing leukocytes at the site of the disease. Especially preferred IL-16 activity inhibitor for use in the therapeutic methods of the present invention are rapamycin and PD098059, and an especially preferred RANTES inhibitor for use in the present invention is compound SB203580.Type: ApplicationFiled: October 19, 2001Publication date: January 30, 2003Inventors: Terry J. Smith, William W. Cruikshank
-
Publication number: 20030021780Abstract: The invention provides a method of reducing the severity of an autoimmune condition associated with T-lymphocyte infiltration. The invention also provides a method of diagnosing or predicting the susceptibility to an autoimmune disease associated with fibroblast mediated T-lymphocyte infiltration. Methods of identifying a substance capable of modulating T-lymphocyte recruitment associated with an autoimmune condition also are provided.Type: ApplicationFiled: May 6, 2002Publication date: January 30, 2003Inventors: Terry J. Smith, William W. Cruikshank
-
Publication number: 20030017990Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans.Type: ApplicationFiled: August 15, 2001Publication date: January 23, 2003Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld